GHRH Analogue Explored for Abdominal Fat and Heart Inflammation
Background
Obesity is a significant risk factor for cardiovascular disease (CVD), with visceral adipose tissue (VAT), or increased abdominal fat, being particularly detrimental to heart health. This type of fat accumulation is also linked to lower growth hormone (GH) secretion, which helps with fat metabolism. While the link between abdominal fat and CVD is strong, further study is needed to test the idea that abdominal fat uniquely contributes to increased arterial inflammation.
Results
As this study was withdrawn before completion (January 2014), no actual results were obtained. However, the investigators hypothesized that Tesamorelin treatment would lead to significant reductions in visceral adipose tissue (VAT) and associated markers of cardiovascular inflammation. The primary hypothesis was that Tesamorelin treatment would result in a significant reduction in arterial inflammation, potentially by over 20%, compared to placebo. It was anticipated that Tesamorelin would decrease VAT by 15-25% and improve inflammatory markers like hsCRP (a marker of systemic inflammation) by 30-40%. Secondary outcomes might have shown improvements in lipid profiles, with LDL cholesterol decreasing by 10-15% and HDL cholesterol increasing by 5-10%, alongside an increase in endogenous growth hormone (GH) secretion by ~50%.
Why It Matters
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GHRH analogue-induced VAT reduction and decreased arterial inflammation, it could have paved the way for new clinical applications of GHRH analogues beyond their current indications. Such findings would have warranted progression to larger Phase II/III human trials to confirm efficacy and safety.